

Dr Mark Vanderpump Audit/Guidelines

AUDIT

I have supervised or participated in the following audits:

1. Audit of strategy of use of TSH alone in thyroid function tests in a DGH laboratory. Vanderpump MPJ, Manning K, Neary RH & Clayton RN (1997).
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=9488012>
2. An audit of management of thyroid cancer in a large district general hospital Vanderpump MPJ, Alexander L, Scarpello JH & Clayton RN (1998).
<http://www3.interscience.wiley.com/journal/119120411/abstract>
3. Analysis of patient knowledge and effectiveness of insulin stress tests performed in patients with pituitary disease within the Department of Endocrinology of the Royal Free Hospital. Brothwood TA & Vanderpump MP. Safety, accuracy and patients' perspectives of insulin tolerance tests: An audit. Endocrine Society 2001, Endo 2001:P1-627.
4. Single centre audit of surgical outcome in acromegaly. SE Baldeweg, GS Conway, M Powell & M Vanderpump. Endocrine Abstracts (2003) 5:P190. <http://www.endocrine-abstracts.org/ea/0005/ea0005p190.htm>
5. Use of continuous glucose monitoring system in the medical management of insulinomas. SE Baldeweg, S Hope, J Tibbals, B Davidson & M Vanderpump. Endocrine Abstracts (2003) 6:DP23.
<http://www.endocrine-abstracts.org/ea/0006/ea0006dp23.htm>
6. An audit of hypoglycaemia in insulin treated patients with type 2 diabetes. Hope SJC, Parker C & Vanderpump MPJ. Hypoglycaemia and insulin treated type 2 diabetes - two insulin regimes compared. Diabetes UK 2004, Diabetes Medicine 21 (Suppl 2):P102.
7. An audit of patients with thyrotoxicosis treated at the Royal Free Hospital has provided data on the relapse rate following treatment with anti-thyroid drugs, radioiodine and surgery as well as providing cost-effectiveness data for the three management approaches. Patel NN, Baker JJ, Abraham P & Vanderpump MPJ. The cost-effectiveness of treatment modalities for thyrotoxicosis - a 2-year follow-up study. American Thyroid Association 2004, Thyroid: 14:700.
8. Audit and review of the new night-team structure in acute medicine to examine quality of care, training opportunities, leadership and team-building and consultant work-load in conjunction with the Medical Director and Postgraduate Dean.
<http://www.ingentaconnect.com/content/rcop/cm/2004/00000004/00000005/art00012>
9. A prospective study using continuous subcutaneous insulin infusion (CSII) for type 1 diabetes at the Royal Free Hospital. Solomon AM, Nethaji C, Holland J, Vanderpump M & Press M. A prospective study using continuous subcutaneous insulin infusion (CSII) for type 1 diabetes in a single centre. Diabetes UK 2008, Diabetes Medicine 25, Suppl 1:OC.
10. Audit of thyroid function testing in a HIV population. Vanderpump MPJ, Kottegoda R, Madge S, Thomas M, Smith C, Lampe F, Harvey R, Johnson M & Youle M. No association between HIV disease and its treatment and thyroid function. British Thyroid Association Autumn Meeting 2005 and

International Thyroid Congress 2005, Thyroid 15 (Suppl. 1):S79-80, and HIV 2006, HIV Medicine 7 (Suppl. 1):P49.<http://www3.interscience.wiley.com/journal/118491584/abstract>

11. Joint audit with the Department of Clinical Biochemistry to investigate the finding of raised serum FT4 and inappropriately detectable serum TSH. Han TS, Woolman E, Johri N, Thomas M, & Vanderpump MP. Raised serum FT4 and inappropriately detectable serum TSH: Evaluation of recommendations from UK TFT guidelines. British Endocrine Societies 2008, Endocrine Abstracts 14:P369, and Endo 2008, P1-360.<http://www.endocrine-abstracts.org/ea/0015/ea0015p369.htm>

12. Joint audit with the Departments of Clinical Biochemistry and Hepatology to determine the incidence of thyroid dysfunction in a Hepatitis C population treated with Interferon and Ribavirin combination therapy. Costelloe S, Wassef N, Morris C, Schulz J, Vaghani T, Thomas M, Jacobs M, Dusheiko G & Vanderpump M. Thyroid dysfunction in a hepatitis C population treated with interferon therapy. British Endocrine Societies 2009, Endocrine Abstracts 19:P353 and American Thyroid Association 2009). <http://www3.interscience.wiley.com/journal/123278763/abstract>

13. Development of audit tool for national study of pituitary apoplexy. Kumar S, Reddy N; Baldeweg S, Han T, Vanderpump M & Wass J. Validity of the new pituitary apoplexy guideline group scoring system (PAGGS) in the management of pituitary apoplexy: a large retrospective review of 46 patients with classical pituitary apoplexy. British Endocrine Societies 2010, Endocrine Abstracts 21:P284. <http://www.endocrine-abstracts.org/ea/0021/ea0021p284.htm>

14. Audit of introduction of TSH receptor antibody assay. Theodoraki K, Jones GL, Patel D, Bunn C, Thomas M, Parker J, Bouloux P-M, Vanderpump M. TSH Receptor Antibody assay: its use in a tertiary centre. British Endocrine Societies 2010, Endocrine Abstracts 21:P389 and International Thyroid Congress, Paris, September 2010. <http://www.endocrine-abstracts.org/ea/0021/ea0021p389.htm>

15. Review of 125 individuals with adrenal incidentalomas: a single centre cohort. Theodoraki K, Jones GL, Patel D, Bunn C, Thomas M, Parker J, Bouloux P-M, Vanderpump M, Khoo B. Society for Endocrinology BES March 2011, Endocrine Abstracts 25:P105. <http://www.endocrine-abstracts.org/ea/0025/ea0025P105.htm>

16. Clinical outcome of radioiodine treatment for Graves' disease at a tertiary care centre. Rathore A, Mathew R, Garg A, Vanderpump M. Society for Endocrinology 2014. Endocrine Abstracts 34:P395. <http://www.endocrine-abstracts.org/ea/0034/ea0034P395.htm>

17. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP; UK Dopamine Agonist Valvulopathy Group (2014). Journal of Clinical Endocrinology and Metabolism 99:90-96. <http://press.endocrine.org/doi/pdf/10.1210/jc.2013-2254>

18. The Royal Free Continuous Subcutaneous Insulin Infusion (CSII) Service: a comparison of patch pump vs traditional pump showing different population demographics, increased patch pump uptake in pregnancy and equal efficacy at reducing HbA1c. N Gostelow, L Williamson, J Holland, M Vanderpump & M Rosenthal. British Diabetes Association March 2014. P476

19. A Study on the Management of Differentiated Thyroid Cancer at a Large UK Teaching Hospital. CL Chang, G Stewart, M Vanderpump, B Khoo, P-M Bouloux, D Afful & S Janmohamed. The Endocrine Society June 2014. P0570.

CLINICAL GUIDELINES

I have participated in the writing and development of following clinical guidelines:

1. Vanderpump MPJ, Ahlquist JAO, Franklyn JA & Clayton RN on behalf of a Working Group of the Research Unit of the Royal College of Physicians and the Endocrinology and Diabetes Committee of the College and Society for Endocrinology (1996). Development of consensus for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. *British Medical Journal*, 313:539-44.
2. Vanderpump MPJ. Epidemiology of subclinical thyroid disease: Expert advisor for Consensus Development Conference on Subclinical Thyroid Disease, Endocrine Society, Washington, September 2002.
3. UK Guidelines for the use of thyroid function tests. The Association of Clinical Biochemistry, British Thyroid Association and the British Thyroid Foundation 2006. http://www.british-thyroid-association.org/TFT_guideline_final_version_July_2006.pdf
4. UK guidelines for the management of pituitary apoplexy. Pituitary Apoplexy Guidelines Development Group (2011). Rajasekaran S, Vanderpump M, Baldeweg S, Drake W, Lanyon M, Markey A, Plant G, Powell M, Sinha S, Wass J. UK guidelines for the management of pituitary apoplexy. *Clinical Endocrinology* 74:9-20.
5. The use of L-T4 + L-T3 in the treatment hypothyroidism: Guidelines of the European Thyroid Association. The European Thyroid Association Taskforce: Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump M. *European Thyroid Journal* 1:55-71.